The U.S. Centers for Disease Control and Prevention (CDC) is tracking toward recommending that Americans get an annual COVID-19 vaccine, the agency’s new director says.
“We’re not quite there yet, but stay tuned. I think within the next couple of weeks, month we’re going to hear more from our experts on COVID shots.”
The CDC didn’t respond to emailed questions, including what it would say to critics who note that there’s a lack of clinical trial data supporting the shots.
Without that data, “you can’t really say what the potential benefit to people is,” Dr. David McCune, an oncologist, told The Epoch Times.
Scaling Back Recommendations
The CDC recommended people of all ages receive a primary series and that they all get at least one booster, too. The agency finally scaled back those recommendations in April, saying that some vaccinated people should not get an additional dose if they’ve already received one of the newer vaccines.The World Health Organization said in the spring that the highest priority is boosting people with compromised immune systems and others who could benefit the most, with the lower priority being on boosting healthy children.
The CDC should consider scaling back even further and not recommending young, healthy people receive a primary series if there continues to be a lack of data from trials and prospective studies, Dr. McCune said.
“When you look at tracking data for the young, the rates of either infection or vaccination—in other words, the rate at which people have some level of circulating immunity—is quite high. And so the idea that that group needs to have a vaccination series now, without current research in that particular population, I don’t think is scientifically valid,” he said.
Updated Shots
As the vaccines have performed increasingly worse against newer variants of COVID-19, U.S. officials and manufacturers have worked together to update the shots to try to increase the performance.Now the companies are preparing to update the shots again to target XBB.1.5, a newer variant of COVID-19, under guidance from the U.S. Food and Drug Administration (FDA). XBB.1.5 was the dominant strain in June, according to the CDC, but was projected to have been largely displaced in July.
The updated shots are expected to be rolled out in September. For the first time, they won’t contain any components of the Wuhan variant, the original strain.
Separately, the Biden administration is spending $5 billion on what it calls Project NextGen, an effort that includes trying to support the development of better vaccines.
Combination Vaccines
Major pharmaceutical companies are preparing combination COVID-19-influenza vaccines and have said they expect tens of millions of Americans to get the shots on an annual basis. The FDA gave Pfizer and BioNTech permission in 2022 to track a candidate that utilizes messenger RNA technology, like their vaccine, the companies said. Moderna is also working on a combination shot.The revenue from the combination shot could help offset the sharp drop in demand for the current slate of COVID-19 vaccines, which are being adopted by a fraction of Americans.
“The companies need a new market for the COVID product and they can get that by combining it with the influenza vaccine and making sure the CDC recommends that everyone get a COVID booster annually,” Barbara Loe Fisher, co-founder and president of the National Vaccine Information Center, told The Epoch Times in an email.
“If CDC officials recommend that everyone get an annual COVID booster shot,” Ms. Fisher said, “it will only further increase public distrust in vaccines and call into question the scientific and moral integrity of public health policy.”